Loading...

Hologic, Inc.

HOLXNASDAQ
Healthcare
Medical - Instruments & Supplies
$67.31
$0.14(0.20%)

Hologic, Inc. (HOLX) Financial Performance & Income Statement Overview

View comprehensive annual and quarterly summaries for Hologic, Inc. (HOLX), featuring income statements, balance sheets, and cash flow data.

Revenue Growth
-0.00%
0.002%
Operating Income Growth
45.15%
45.15%
Net Income Growth
73.14%
73.14%
Operating Cash Flow Growth
22.26%
22.26%
Operating Margin
17.52%
17.52%
Gross Margin
51.80%
51.80%
Net Profit Margin
13.79%
13.79%
ROE
11.51%
11.51%
ROIC
9.02%
9.02%

Hologic, Inc. (HOLX) Income Statement & Financial Overview

Explore comprehensive income reports for Hologic, Inc. HOLX, broken down by year and quarter.

MetricQ2 2025Q1 2025Q4 2024Q3 2024
Revenue$1.005B$1.02B$987.90M$1.01B
Cost of Revenue$623.30M$446.00M$430.30M$443.10M
Gross Profit$382.00M$575.80M$557.60M$568.30M
Gross Profit Ratio$0.38$0.56$0.56$0.56
R&D Expenses$61.50M$60.30M$67.30M$64.10M
SG&A Expenses$274.10M$281.80M$249.20M$240.30M
Operating Expenses$384.30M$350.70M$327.60M$304.40M
Total Costs & Expenses$1.01B$792.00M$757.80M$747.50M
Interest Income$14.90M$24.20M$28.40M$28.40M
Interest Expense$29.10M$30.50M$31.90M$31.90M
Depreciation & Amortization$48.20M$74.00M$74.60M$72.30M
EBITDA-$7.00M$352.00M$328.10M$344.90M
EBITDA Ratio-$0.007$0.34$0.33$0.34
Operating Income-$7.00M$229.80M$230.10M$263.90M
Operating Income Ratio-$0.007$0.22$0.23$0.26
Other Income/Expenses (Net)-$21.50M$17.70M-$8.50M-$23.20M
Income Before Tax-$28.50M$247.50M$221.60M$240.70M
Income Before Tax Ratio-$0.03$0.24$0.22$0.24
Income Tax Expense-$11.10M$46.50M$43.00M$46.20M
Net Income-$17.40M$201.00M$178.60M$194.50M
Net Income Ratio-$0.02$0.20$0.18$0.19
EPS-$0.08$0.87$0.76$0.83
Diluted EPS-$0.08$0.87$0.76$0.82
Weighted Avg Shares Outstanding$225.77M$230.28M$233.77M$234.60M
Weighted Avg Shares Outstanding (Diluted)$225.77M$232.11M$235.97M$236.47M

The company's financials show resilient growth, with revenue advancing from $1.01B in Q3 2024 to $1.005B in Q2 2025. Gross profit remained healthy with margins at 38% in Q2 2025 compared to 56% in Q3 2024. Operating income hit -$7.00M last quarter, sustaining a consistent -1% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$7.00M. Net income dropped to -$17.40M, while earnings per share reached -$0.08. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;